Our results suggest that GLIPR1 deserves further investigation in the context of NSCLC and further investigation is required to verify GLIPR1 has the potential to be a novel therapeutic target for DDP-resistant NSCLC patients. The gene discussed is GLIPR1; the disease is non-small cell lung carcinoma.